Company intelligence / Profile preview

Advent Therapeutics, Inc.

Doylestown, Pennsylvania, United Statesadvent-therapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Advent Therapeutics has developed a proprietary formulation of optimized retinol palmitate (vitamin A) for preterm infants. Their lead product for BPD prevention has received orphan drug designation in the US and Europe. The company has received over $6 million in NIH grants for neonatal programs, including a recent $3 million grant to accelerate development of their aerosolized vitamin A formulation.

Therapeutic areas: OphthalmologyPulmonologyInfectious Diseases
Modalities: Small molecule drugVitamin A (retinol palmitate)
Industry: Biotech

Drug pipeline

1 asset

retinol palmitate

Pre-clinical

Indications: Bronchopulmonary dysplasia, Retinopathy of prematurity, Acute lung injury

Partnerships

National Institutes of Health (NIH)

Beyond the preview

Go deeper on Advent Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advent Therapeutics, Inc..

Explore the full profile